The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups. -
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Blast Count Prognostic for CML Presenting in Advanced Phase
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
